Literature DB >> 7615279

Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A.

T Oriishi1, M Sata, A Toyonaga, E Sasaki, K Tanikawa.   

Abstract

This study looked at the intestinal permeability and the immune response to enteric bacterial antigens in patients with inflammatory bowel disease (IBD). They were evaluated by using a lactulose tolerance test and measuring blood anti-lipid A antibody concentrations, respectively. The lactulose tolerance tests were performed 22 times in 14 patients with Crohn's disease (CD), 19 times in 12 patients with ulcerative colitis (UC), and 12 times in 12 healthy controls. Blood lactulose concentrations were measured after oral administration every two hours for eight hours, also blood C reactive protein concentrations and anti-lipid A antibody concentrations were measured just before lactulose administration. Blood lactulose concentrations were significantly higher in patients with CD than in the controls from two to eight hours after administration, while in UC they were significantly higher than in the controls from six to eight hours. Maximum blood lactulose concentrations in each tolerance test in patients with the active phase significantly exceeded those in the inactive phase of either CD or UC. A significant correlation was also seen between the maximum blood lactulose concentrations and the C reactive protein concentrations. Blood anti-lipid A antibody concentrations in patients with CD were significantly higher than in the controls as well as in patients with UC in immunoglobulin (Ig) A class and IgG class. In UC they were significantly higher than in the controls in IgA class. But, they were not related to the severity of the disease of either CD or UC, and not correlated significantly with the maximum blood lactulose concentrations in either CD or UC. The intestinal permeability and the immune response to enteric bacterial antigens in patients with inactive CD were significantly increased over those in the controls as well as in patients with inactive UC. These findings suggest that an increase of the intestinal permeability and that of producing antibodies to enteric bacterial antigens are both important for the pathogenesis of IBD, and that the characteristics of CD and UC differ.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615279      PMCID: PMC1382628          DOI: 10.1136/gut.36.6.891

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

Review 1.  Bacterial endotoxins. The second Carl Prausnitz Memorial Lecture.

Authors:  O Westphal
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

2.  Chromium 51-ethylenediaminetetraacetate test: a useful test in the assessment of inflammatory bowel disease.

Authors:  C A O'Morain; A C Abelow; L R Chervu; G M Fleischner; K M Das
Journal:  J Lab Clin Med       Date:  1986-11

Review 3.  Human IgG subclasses in health and disease. (A review). Part II.

Authors:  F Shakib; D R Stanworth
Journal:  Ric Clin Lab       Date:  1980 Oct-Dec

4.  Determination of anti-lipid A and lipid A by enzyme immunoassay.

Authors:  P C Fink; C Galanos
Journal:  Immunobiology       Date:  1981       Impact factor: 3.144

5.  Crohn's disease: maintenance of remission by diet.

Authors:  V A Jones; R J Dickinson; E Workman; A J Wilson; A H Freeman; J O Hunter
Journal:  Lancet       Date:  1985-07-27       Impact factor: 79.321

6.  Studies of intestinal permeability in inflammatory diseases using polyethylene glycol 400.

Authors:  R T Jenkins; R L Goodacre; P J Rooney; J Bienenstock; T Sivakumaran; W H Walker
Journal:  Clin Biochem       Date:  1986-10       Impact factor: 3.281

7.  Circulating lipid A antibodies despite absence of systemic endotoxemia in patients with Crohn's disease.

Authors:  W Kruis; P Schussler; M Weinzierl; C Galanos; J Eisenburg
Journal:  Dig Dis Sci       Date:  1984-06       Impact factor: 3.199

8.  Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis.

Authors:  R G Farmer; G Whelan; V W Fazio
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

9.  Long term prognosis in ulcerative colitis--based on results from a regional patient group from the county of Copenhagen.

Authors:  C Hendriksen; S Kreiner; V Binder
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

10.  Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen.

Authors:  V Binder; C Hendriksen; S Kreiner
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

View more
  9 in total

1.  Smoking and inflammatory bowel diseases: what in smoking alters the course?

Authors:  A M El-Tawil
Journal:  Int J Colorectal Dis       Date:  2010-03-24       Impact factor: 2.571

2.  Lipopolysaccharide-Induced Increase in Intestinal Permeability Is Mediated by TAK-1 Activation of IKK and MLCK/MYLK Gene.

Authors:  Meghali Nighot; Manmeet Rawat; Rana Al-Sadi; Eliseo F Castillo; Prashant Nighot; Thomas Y Ma
Journal:  Am J Pathol       Date:  2019-02-01       Impact factor: 4.307

3.  Lipopolysaccharide Regulation of Intestinal Tight Junction Permeability Is Mediated by TLR4 Signal Transduction Pathway Activation of FAK and MyD88.

Authors:  Shuhong Guo; Meghali Nighot; Rana Al-Sadi; Tarik Alhmoud; Prashant Nighot; Thomas Y Ma
Journal:  J Immunol       Date:  2015-10-14       Impact factor: 5.422

4.  Conclusive evidence of endotoxaemia in biliary obstruction.

Authors:  W D Clements; P Erwin; M D McCaigue; I Halliday; G R Barclay; B J Rowlands
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

5.  Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission.

Authors:  Andrew Szilagyi; Julie Rivard; Ian Shrier
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

Review 6.  Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?

Authors:  Hiroshi Fukui
Journal:  Inflamm Intest Dis       Date:  2016-07-20

7.  Endotoxin neutralization as a biomonitor for inflammatory bowel disease.

Authors:  Keith Champion; Laura Chiu; John Ferbas; Michael Pepe
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  Lactobacillus johnsonii glycolipids, their structure and immunoreactivity with sera from inflammatory bowel disease patients.

Authors:  Mariola Paściak; Sabina Górska; Natalia Jawiarczyk; Andrzej Gamian
Journal:  Microb Biotechnol       Date:  2016-10-21       Impact factor: 5.813

9.  Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.

Authors:  S Keely; E L Campbell; A W Baird; P M Hansbro; R A Shalwitz; A Kotsakis; E N McNamee; H K Eltzschig; D J Kominsky; S P Colgan
Journal:  Mucosal Immunol       Date:  2013-05-22       Impact factor: 7.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.